Physician profile
Caitlin Innerfield
NPI 1548492127
$97,215.53
in general payments reported to CMS, 2019-2025
51 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $924 · 2021: $15K · 2022: $20K · 2023: $32K · 2024: $27K · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $25K · Food and Beverage: $3,817 · Honoraria: $3,144 · Travel and Lodging: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,942.00 |
| Consulting Fee | $24,631.92 |
| Food and Beverage | $3,816.96 |
| Honoraria | $3,144.00 |
| Travel and Lodging | $2,344.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $85,428.98 | 2019-2025 | Ztlido |
| Horizon Therapeutics Plc | $4,782.48 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,023.60 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $816.29 | 2019-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $594.75 | 2019-2025 | Proclaim, Octrode |
| Nevro Corp. | $592.65 | 2019-2024 | Senza |
| Boston Scientific Corporation | $444.77 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Si-Bone, INC. | $339.16 | 2020-2025 | |
| Pfizer INC. | $331.51 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $309.66 | 2020-2021 | |
| Medtronic, INC. | $253.66 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Accurian |
| Kowa Pharmaceuticals America, INC. | $244.01 | 2022-2023 | Seglentis, Livalo |
| Redhill Biopharma INC. | $211.61 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $195.27 | 2019-2021 | |
| Saluda Medical Americas, INC. | $160.74 | 2025 | Evoke |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Innerfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.